Inclusion Criteria:  Histologically or cytologically confirmed prostate adenocarcinoma in the very low or low or favorable intermediate risk risk stratification groups (i.e. Gleason Grade groups 1 and 2) and eligible for radiation therapy. Ability to receive prostatic artery embolization within 6-12 weeks of definitive radiation therapy. Ability to understand and the willingness to sign a written informed consent document Prostate larger than 60 grams but less than 150 grams, as assessed by imaging scans American Urologic Association (AUA) or International Prostate Symptom Score (IPSS) Score ≥ 15 Normal organ and marrow function as defined in protocol  Exclusion Criteria:  Receiving androgen deprivation therapy (ADT) Patients with unfavorable intermediate (Gleason Grade Group 3) or high risk localized PCa (Gleason Grade Groups 4 and 5) Receiving any investigational agents for the explicit purpose of prostatic size reduction Inability to receive prostatic artery embolization (PAE) within 6-12 weeks of definitive radiation therapy Active urinary tract infection (UTI) History of severe allergic reaction to intravenous contrast media (iodinated and gadolinium- based) or any agents used during the PAE; patient cannot be medicated against allergic reaction prior to PAE. Active cystolithiasis or prostatitis Inability to have multi-parametric magnetic resonance imaging (mpMRI) Prior transurethral resection of the prostate (TURP) within 2 years Prostate size greater than or equal to150 grams Vulnerable subjects (e.g., inmates and developmentally delayed adults) who are subjects for whom the study may be unsafe or whose rights may be violated with enrollment.